Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Purpose Our objectives were (1) to compare the disposition and in vivo release of paclitaxel between a tocopherol-based Cremophor-free formulation (Tocosol Paclitaxel) and Cremophor EL-formulated paclitaxel (Taxol) in human subjects, and (2) to develop a mechanistic model for unbound and total paclitaxel pharmacokinetics. Methods A total of 35 patients (average +/- SD age: 59 +/-13 years) with advanced non-hematological malignancies were studied in a randomized two-way crossover trial. Patients received 175 mg/m(2) paclitaxel as 15 min (Tocosol Paclitaxel) or 3 h (Taxol) intravenous infusion in each study period. Paclitaxel concentrations were determined by LC-MS/MS in plasma ultrafiltrate and whole blood. NONMEM VI was used for population pharmacokinetics. Results A linear disposition model with three compartments for unbound paclitaxel and a one-compartment model for Cremophor were applied. Total clearance of unbound paclitaxel was 845 L/h (variability: 25% CV). The prolonged release with Tocosol Paclitaxel was explained by the limited solubility of unbound paclitaxel of 405 ng/mL (estimated) in plasma. The 15 min Tocosol Paclitaxel infusion yielded a mean time to 90% cumulative input of 1.14 +/- 0.16 h. Tocosol Paclitaxel was estimated to release 9.8% of the dose directly into the deep peripheral compartment. The model accounted for the presence of drug-containing nanodroplets in blood. Conclusions Population pharmacokinetic analysis indicated linear disposition and a pote…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It should be pointed out that both Wan et al. [188] and Bulitta et al. [248] models relied on stability of the micelles and did not account for a situation where formulation could influence the unbound drug concentration, like in the case of equilibrium micelle binding.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [248]
In the citing paper
“This has also been studied earlier by Bulitta et al., who came to develop similar models to represent the regular micelle and emulsions systems [248].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [248]
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Simplified calculation of body surface area
(1987) · New England Journal of Medicine · doi:10.1056/nejm198710223171717 · Cited by 3,238 · cited 1×
“The BSA was calculated by the Mosteller formula [24] and used to describe body size and to scale all clearance and volume terms linearly by BSA.”
MethodHypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174
Ibrahim, N. K., Desai, N. P., Legha, S. S., Soon‐Shiong, P., Theriault, R. L., Rivera, E., Esmaeli, B., Ring, S. E., Bedikian, A. Y., Hortobágyi, G. N., et al. (2002) · PubMed · Cited by 705
Clinical toxicities encountered with paclitaxel (Taxol).
Rowinsky, E. K., Eisenhauer, E. A., Chaudhry, V., Sg, A., & Rc, D. (1993) · PubMed · Cited by 692
Gianni, L., Kearns, C. M., Giani, A., Capri, G., Viganó, L., Lacatelli, A., Bonadonna, G., & Egorin, M. J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.180 · Cited by 553
(1999) · PubMed · Cited by 337
Self-citationSparreboom, A., van Tellingen, O., Nooijen, W. J., & Beijnen, J. H. (1996) · PubMed · Cited by 313
Role of Formulation Vehicles in Taxane Pharmacology
van Zuylen, L., Verweij, J., & Sparreboom, A. (2001) · Investigational New Drugs · doi:10.1023/a:1010618632738 · Cited by 293
Wiernik, P. H., Schwartz, E. L., Einzig, A., Strauman, J. J., Lipton, R. B., & Dutcher, J. P. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.8.1232 · Cited by 275
Research works printed but not linked: 1
- Beal SL, Sheiner LB, Boeckmann AJ (2006) NONMEM Users Guides (1989–2006). Icon Development Solutions, Ellicott City
Cited by
Cragg, G. M., & Pezzuto, J. M. (2016) · Medical Principles and Practice · doi:10.1159/000443404 · Cited by 798
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Paclitaxel Nano-Delivery Systems: A Comprehensive Review
Ma, P. (2013) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000164 · Cited by 559
Nanocarrier for Poorly Water-Soluble Anticancer Drugs—Barriers of Translation and Solutions
Narvekar, M., Xue, H. Y., Eoh, J. Y., & Wong, H. L. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0107-x · Cited by 257
(2019) · Profiles of Drug Substances, Excipients and Related Methodology · doi:10.1016/bs.podrm.2018.11.001 · Cited by 159
Metadata
- Authors
- Bulitta, J. B., Zhao, P., Arnold, R. D., Kessler, D. R., Daifuku, R., Pratt, J., Luciano, G., Hanauske, A.-R., Gelderblom, H., Awada, A., & Jusko, W. J.
- Affiliations
- University at Buffalo, State University of New York (US)
- University of Georgia (US)
- Asklepios Klinik St. Georg (DE)
- Leiden University Medical Center (NL)
- Institut Jules Bordet (BE)
- Corresponding author
- Jusko, William J.
- ORCID
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2008-09-13
- Volume
- 63
- Issue
- 6
- Pages
- 1049-1063
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2089920524
- Cited by
- 47
- References
- 45
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 4 · 2018: 3 · 2017: 5 · 2016: 3 · 2015: 4 · 2014: 2 · 2013: 6 · 2012: 5
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- paclitaxel, Cremophor EL, population pharmacokinetic model, drug release kinetics, bioavailability, infusion duration, non-hematological malignancies
- MeSH terms
- Adult, Antineoplastic Agents, Phytogenic, Chemistry, Pharmaceutical, Chromatography, Liquid, Female, Humans, Leukocyte Count, Male, Middle Aged, Models, Biological, Monte Carlo Method, Neoplasms, Structure-Activity Relationship, Tissue Distribution, Linear Models, Drug Delivery Systems, Paclitaxel, Cross-Over Studies, Tandem Mass Spectrometry, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. https://app.cochat.ai/papers/10.1007/s00280-008-0827-2
- The paper
- Bulitta, J. B., Zhao, P., Arnold, R. D., Kessler, D. R., Daifuku, R., Pratt, J., Luciano, G., Hanauske, A.-R., Gelderblom, H., Awada, A., & Jusko, W. J. (2009). Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-008-0827-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.